

upon further consideration , the Office deemed the elected claims to be directed to the following patentably distinct species:

- (a) a 1,5-substituted deoxyuridine derivative or analog;
- (b) substituted furanopyrimidone derivative or analog;
- (c) phosphoramidatyl deoxyuridine; and
- (d) 5'-phosphoryl deoxyuridine.

Applicant elects, with traverse, to prosecute species (c), identified above. Upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species that are written in dependent form or which otherwise include all the limitations of an allowed generic claim as provided in 37 C.F.R. § 1.141.

CONCLUSION

No fee, other than the fee for the one month extension of time, is deemed necessary in connection with the filing of this Response. However, if the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-2518**, referencing billing number 2023896-7008412001. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Should a telephone advance prosecution of the subject application, the Examiner is invited to contact the undersigned at (650) 849-4950.

DATE: September 3, 2003

Respectfully submitted,

By: _____

Antoinette F. Konski
Antoinette F. Konski

Registration No.: 34,202

Bingham McCutchen LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111
Telephone: (650) 849-4950
Telefax: (650) 849-4800